LBLinn Persson Berg

Linn Persson Berg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Linn Persson Berg has a total of 38 co-authors. Here are the top co-authors by number of shared publications:

  • Tomas Bergström

    Department of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden

    2 shared publications
  • A Mörner

    Department of Microbiology, The Public Health Agency of Sweden, Solna, Sweden

    1 shared publication
  • A Tegnell

    Department of Public Health Analysis and Data Management, The Public Health Agency of Sweden, Solna, Sweden

    1 shared publication
  • Anna Fogdell-Hahn

    Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden

    1 shared publication
  • Barbara Rath

    Vaccine Safety Initiative, 10437 Berlin, Germany

    1 shared publication
  • Chrysanthi Skevaki

    European Society of Clinical Microbiology and Infectious Diseases Study Group for Respiratory Viruses, ESCMID, Basel

    1 shared publication

Latest Publications

  • The Care Continuum of Patients With Influenza in the Post–COVID-19 Era: A Position Paper

    by Stamatis Karakonstantis, Theodore Lytras, Siran Keske, Sotirios Tsiodras, Lea Papst, Petros Ioannou, Petar Velikov, Linn Persson Berg, Giulia De Angelis, Virginie Prendki, et al.

    This position paper addresses the evolving care continuum for patients with respiratory viral infections in the context of the post–coronavirus disease 2019 pandemic phase. We emphasize the need to place the patient at the center of attention from the first signs of influenza-like illness to recovery. Current practices have revealed several deficiencies, such as timely access to healthcare, fragmentation of care, and inadequate follow-up instructions. This article proposes means to address these deficiencies and discusses diagnostic and management considerations for patients with suspected influenza infection.


  • Open Access

    Serum IgG levels to Epstein-Barr and measles viruses in patients with multiple sclerosis during natalizumab and interferon beta treatment

    by Linn Persson Berg, Marcus Eriksson, Sonia Longhi, Ingrid Kockum, Clemens Warnke, Elisabeth Thomsson, Malin Bäckström, Tomas Olsson, Anna Fogdell-Hahn, Tomas Bergström

    Background: Patients with multiple sclerosis (MS) demonstrate higher seroprevalence of Epstein-Barr virus (EBV) and increased anti-EBV IgG levels in serum compared with healthy controls. Intrathecal antibody production to measles virus (MeV) is a common finding in patients with MS. Objective: To measure serum IgG reactivity to EBV glycoprotein 350 (gp350) and MeV nucleocapsid protein (NCORE) in patients with MS and healthy controls and to determine if reactivity changed in patients during interferon beta (IFNβ) and/or natalizumab (NAT) treatment. A secondary aim was to determine the seroprevalence of EBV in patients and controls. Methods: Patients with MS (n=728) were included from the Swedish pharmacovigilance study for NAT. Paired serum samples from 714 patients drawn before and during NAT treatment and paired samples from 170 patients during prior IFNβ treatment were analysed. In total, 156 patients were included in both groups. Samples from 144 matched blood donors served as controls. Indirect ELISA was applied using recombinant EBVgp350 and MeV NCORE as antigens. EBVgp350 IgG seronegative samples were also analysed using EBV nuclear antigen 1 and viral capsid antigen (VCA). Results: Patients with MS showed higher serum levels of anti-EBVgp350 and anti-MeV NCORE IgG compared with controls. During NAT treatment, the levels of anti-EBVgp350 and anti-MeV NCORE IgG declined, compared with the relatively stable levels noted during prior IFNβ treatment. Ten patients failed to demonstrate anti-EBVgp350 IgG but did show detectable anti-VCA IgG, indicating EBV seropositivity. In contrast, 10/144 controls were EBV seronegative. Conclusions: Treatment with NAT, which is considered a selective immunosuppressive agent with a compartmentalised effect on the central nervous system, appeared to be associated with a moderate decrease in circulating IgG levels to EBVgp350 and MeV NCORE. All patients with MS were EBV IgG seropositive, supporting the potential role of EBV in the pathogenesis of MS.


  • Open Access

    Severe chickenpox disease and seroprevalence in Sweden – implications for general vaccination

    by K Widgren, L Persson Berg, A Mörner, L Lindquist, A Tegnell, J Giesecke, M Studahl


  • Open Access

    Recombinant Epstein-Barr virus glycoprotein 350 as a serological antigen

    by Linn Persson Berg, Elisabeth Thomsson, Gentiana Hasi, Malin Bäckström, Tomas Bergström


  • Open Access

    CXCL11 production in cerebrospinal fluid distinguishes herpes simplex meningitis from herpes simplex encephalitis

    by Liza Lind, Marie Studahl, Linn Persson Berg, Kristina Eriksson

    The closely related herpes simplex viruses 1 and 2 can cause inflammations of the central nervous system (CNS), where type 1 most often manifest as encephalitis (HSE), and type 2 as meningitis (HSM). HSE is associated with severe neurological complications, while HSM is benign in adults. We proposed that studying the chemokine and cytokine production in cerebrospinal fluid (CSF) and serum could indicate why two closely related viruses exhibit different severity of their accompanied CNS inflammation. Secretion patterns of 30 chemokines and 10 cytokines in CSF of adult patients with acute HSE (n = 14) and HSM (n = 20) in the initial stage of disease were analyzed and compared to control subjects without viral central nervous system infections and to levels in serum. Most measured chemokines and cytokines increased in CSF of HSE and HSM patients. Overall, the CSF chemokine levels were higher in CSF of HSM patients compared to HSE patients. However, only five chemokines reached levels in the CSF that exceeded those in serum facilitating a positive CSF-serum chemokine gradient. Of these, CXCL8, CXCL9, and CXCL10 were present at high levels both in HSE and HSM whereas CXCL11 and CCL8 were present in HSM alone. Several chemokines were also elevated in serum of HSE patients but only one in HSM patients. No chemokine in- or efflux between CSF and serum was indicated as the levels of chemokines in CSF and serum did not correlate. We show that HSM is associated with a stronger and more diverse inflammatory response in the CNS compared to HSE in the initial stage of disease. The chemokine patterns were distinguished by the exclusive local CNS production of CXCL11 and CCL8 in HSM. Inflammation in HSM appears to be restricted to the CNS whereas HSE also was associated with systemic inflammation.